Coridea invented a new therapy, Aquapheresis, which allows for the safe and expedient removal of large volumes of fluid. Patients receiving Aquapheresis showed a remarkable 50 percent reduction in the number of re-hospitalizations for heart failure over the standard of care in trials. CHF Solutions Inc. obtained FDA approval of the Aquadex™ System, which is now considered standard of care for drug resistant fluid overload. Gambro AB acquired CHF Solutions in 2010.
CHF Solutions
